Low-dosage metronomic chemotherapy and angiogenesis: Topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis

APMIS

Volumn 120, Issue 2, 2012, Pages 147-156

  Albertsson, Per ^a   Lennernäs, Bo ^a   Norrby, Klas ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Angiogenesis; Irinotecan; Metronomic chemotherapy; Mitoxantrone; Rat; Reactive oxygen species; VEGF

Indexed keywords

IRINOTECAN; MITOXANTRONE; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; LOW DRUG DOSE; MALE; METRONOMIC DRUG ADMINISTRATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ANIMALS; BODY WEIGHT; CAMPTOTHECIN; ENDOTHELIAL CELLS; MALE; MESENTERY; MITOXANTRONE; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; STATISTICS, NONPARAMETRIC; TOPOISOMERASE INHIBITORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84855706050     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2011.02830.x     Document Type: Article

References (58)

1. Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O'Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86.
2. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-r antibody induces sustained tumor regression without over toxicity. J Clin Invest 2000;105:R1-8.
3. Folkman J. Angiogenesis and apoptosis. Sem Cancer Biol 2003;13:159-67.
4. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;105:1045-7.
5. Blansfield JA, Caragacianu D, Alexander HRIII, Tanrea MA, Morita SY, Lorang D, et al. Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res 2008;14:270-80.
6. Bocci G, Falcone A, Fioravanti A, Orlandi P, Di Paolo A, Fanelli G, et al. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer 2008;98:1619-29.
7. Banissi C, Ghiringhelli F, Chen L, Carpantier AF. Treg depletion with low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother 2009;52:1627-34.
8. Reuveni D, Halperin D, Fabian I, Tsarfaty G, Askenasy N, Shalit I. Moxifloxacin increases anti-tumor and anti-angiogenic activity of irinotecan in human xenograft tumors. Biochem Pharmacol 2010;79:1100-7.
9. Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, et al. High-dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res 2006;12:5190-8.
10. Orlando L, Cardillo A, Rocca A, Balduzzi A, Ghisini R, Peruzzotti G, et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs 2006;17:961-7.
11. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56:641-8.
12. Lord R, Nair S, Schache A, Spicer J, Somaihah N, Khoo V, et al. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol 2007;177:2136-40.
13. Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008;26:4899-905.
14. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008;26:76-82.
15. Sánchez-Munoz A, Pérez-Ruiz E, Ribelles N, Marquez A, Alba W. Maintenance treatment in metastatic breast cancer. Expert Rev Anti-Cancer Ther 2008;8:1907-12.
16. Panigrahy D, Kaipainen A, Butterfield CE, Chaponis DM, Laforme AM, Folkman J, et al. Inhibition of tumor angiogenesis by oral etoposide. Exp Ther Med 2010;1:739-46.
17. Norrby K. In vivo models of angiogenesis. J Cell Mol Med 2006;10:588-612.
18. Norrby K. Drug testing with angiogenesis models. Expert Opin Drug Discov 2008;3:533-49.
19. Albertsson P, Lennernäs B, Norrby K. On metronomic chemotherapy: modulation of angiogenesis modulated by VEGF-A. Acta Oncol 2006;45:144-55.
20. Norrby K, Nordenhem A. Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo. APMIS 2010;118:949-57.
21. Lennernäs B, Albertsson P, Lennernäs H, Norrby K. Chemotherapy and antiangiogenesis: drug-specific, dose-related effects. Acta Oncol 2003;42:294-303.
22. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010;102:1555-77.
23. Norrby K. Vascular endothelial growth factor and de novo mammalian angiogenesis. Microvasc Res 1996;51:153-63.
24. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966;50:219-44.
25. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002;94:883-90.
26. St. Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, et al. Genes expressed in human tumor endothelium. Science 2000;289:1197-202.
27. Norrby KC. Rat mesentery angiogenesis assay. J Vis Exp 2011;52:e3078, DOI: 10.3791/3078.
28. Lennernäs B, Albertsson P, Damber J-E, Norrby K. Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non-tumor tissue in the same animals: a quantitative study. APMIS 2004;112:201-9.
29. Mukhopadhay D, Nagy JA, Manseau EJ, Dvorak HF. Vascular permeability factor/vascular endothelial growth factor-mediated signaling in mouse mesentery vascular endothelium. Cancer Res 1998;58:1278-84.
30. Norrby K, Mattsby-Baltzer I, Innocenti M, Tuneberg S. Orally administered bovine lactoferrin systemically inhibits VEGF165-mediated angiogenesis in the rat. Int J Cancer 2001;91:236-40.
31. Shimamura M, Yamamoto Y, Ashino H, Oikawa T, Hazato T, Tsuda H, et al. Bovine lactoferrin inhibits tumor-induced angiogenesis. Int J Cancer 2004;111:111-6.
32. Takano S, Kamiyama H, Mashiko R, Osuka S, Ischikawa E, Matsumura A. Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth. J Neurooncol 2010;99:177-85.
33. Sidker H, Huso DL, Zhang H, Wang B, Ryu B, Hwang ST, et al. Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors. Cancer Cell 2003;4:291-9.
34. Rohan RM, Fernandez A, Udagawa T, Tuan J, D'Amato RJ. Genetic heterogeneity of angiogenesis in mice. FASEB J 2000;14:871-6.
35. Polverini PJ, Novak RF. Inhibition of angiogenesis by the antineoplastic agents mitoxantrone and bisantrene. Biochem Biophys Res Commun 1986;140:901-7.
36. Iigo M, Shimamura M, Sagawa K, Tsuda H. Characteristics of the inhibitory effect of mitoxantrone and pirarubicin on lung metastases of colon carcinoma. Jpn J Cancer Res 1995;86:867-72.
37. O'Leary JJ, Shapiro RL, Ren CJ, Chuang N, Cohen HW, Potmesil M. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, toptecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res 1999;5:181-7.
38. Hashimoto K, Man S, Xu P, Ceuz-Munoz W, Tang T, Kumar R, et al. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther 2010;9:996-1006.
39. Kaneko S, Ishibashi M, Kaneko M. Vascular endothelial growth factor expression is closely related to irinotecan-mediated inhibition of tumor growth and angiogenesis in neoroblastoma zenografts. Cancer Sci 2008;99:1209-17.
40. Kamiyama H, Takano S, Tsuboi K, Matsumura A. Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. J Cancer Res Clin Oncol 2005;131:205-13.
41. Albertsson P, Lennernäs B, Norrby K. Dose effects of continuous vinblastine chemotherapy on mammalian angiogenesis by VEGF-A. Acta Oncol 2008;47:293-300.
42. Albertsson P, Lennernäs B, Norrby K. Low-dose continuous 5-fluorouracil infusion stimulates VEGF-A-mediated angiogenesis. Acta Oncol 2009;48:418-25.
43. Eberlein M, Scheibner KA, Black KE, Collins SL, Chan-Li Y, Powell JD, et al. Anti-oxidant inhibition of hyaluronan fragment-induced inflammatory gene expression. J Inflamm 2008;5:20.
44. Ushio-Fukai M, Nakamura Y. Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett 2008;266:37-52.
45. Bonello S, Zähriner C, BelAiba RS, Djordjevic T, Hess J, Michiels C, et al. Reactive oxygen species activate the HIF-1 alpha promoter via a functional NF-kB site. Arterioscler Thromb Vasc Biol 2007;27:755-61.
46. Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991;51:794-8.
47. Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther 2004;3:294-300.
48. Arbiser JL, Petros J, Klafter R, Govindajaran B, McLaughlin ER, Brown LF, et al. Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc Natl Acad Sci U S A 2002;99:715-20.
49. Sen CK, Khanna S, Babior BM, Hunt TK, Ellison EC, Roy S. Oxidant-induced vascular endothelial growth factor expression in human keratinocytes and cutaneous wound healing. J Biol Chem 2002;277:33284-90.
50. Lo YY, Wong JM, Cruz TF. Reactive oxygen species mediate cytokine activity of c-Jun NH2-terminal kinases. J Biol Chem 1996;271:15703-7.
51. Miebach S, Grau S, Hummel V, Rieckman P, Tonn J-C, Goldbrunner PH. Isolation and culture of microvascular endothelial cells from gliomas of different WHO grades. J Neurooncol 2006;76:39-48.
52. Grzelak A, Rychlik B, Baptosz G. Light-dependent generation of reactive oxygen species in cell culture media. Free Radic Biol Med 2001;30:1418-25.
53. Craig LE, Spelman JP, Strandberg JD, Zink MC. Endothelial cells from diverse tissues exhibit differences in growth and morphology. Microvasc Res 1998;55:65-76.
54. Murphy HS, Bakopoulos N, Same MK, Varani J, Ward PA. Heterogenetity of vascular endothelial cells: differences in susceptibility to neutrophil-mediated injury. Microvasc Res 1998;56:203-11.
55. Klement GL, Yip TT, Cassiola F, Kikuchi L, Cervi D, Podust V, et al. Platelets actively sequester angiogenesis regulators. Blood 2009;113:2835-42.
56. Menard C, Martin F, Apetoh L, Bouyer F, Ghiringhelli F. Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother 2008;57:1579-87.
57. Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci USA 2003;100:12917-22.
58. Damber JE, Vallbo C, Albertsson P, Lennernäs B, Norrby K. The anti-tumor effect of low-dose chemotherapy may partly be mediated by thrombospondin. Cancer Chemother Pharmacol 2006;58:354-60.